Journal article

Publication year: 2018

Pages: 345-34+

Journal: Deutsches Ärzteblatt International

Volume number: 115

Issue number: 20-21

ISSN: 1866-0452

Open access status: Green

DOI Link: https://doi.org/10.3238/arztebl.2018.0345

Publisher: Deutscher Ärzte-Verlag

Abstract: 

Background: Rates of colonization and infection with carbapenem-resistant Gram-negative pathogens are on the rise, particularly in southeastern European countries, and this is increasingly true in Germany as well. The organisms in question include enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli and non-fermenting bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. As the carbapenems have been the gold standard to date for the systemic treatment of serious infections with Gram-negative bacteria, carbapenem resistance presents new and difficult challenges in therapeutic decision-making, particularly because of the high frequency of co-resistance.

Methods: This review is based on pertinent publications retrieved by a selective search in PubMed and on other applicable literature.

Results: Multiresistant Gram-negative (MRGN) pathogens are classified in Germany according to their resistance to four different classes of antibiotics; fluoroquinolones, piperacillin, third-generation cephalosporins, and carbapenems. Quadruple MRGN pathogens are resistant to all four groups, triple MRGN pathogens to three of them. There are a number of therapeutic alternatives to carbapenems that can be applied with the aid of sensitive microbiological and/or molecular genetic testing. The following antibiotics are often the only ones that can be used to treat quadruple MRGN pathogens: colistin, aminoglycosides, tigecycline, fosfomycin, ceftazidime/avibactam, and ceftolozan/tazobactam. Carbapenems, too, may still be an option in certain situations. There is also evidence that combinations of antibiotics against which the pathogen is resistant individually can sometimes be a valid treatment option; these include combinations of colistin with one or two carbapenems.

Conclusion: The treatment of severe infection with carbapenem-resistant pathogens should be individualized and carried out in an interdisciplinary framework, in consideration of antibiotic pharmacokinetics and pharmacodynamics in each case. The treatment options are based on evidence from in vitro studies, retrospective studies, and case series, which must be interpreted with caution. Randomized clinical trials are needed to test each of the various combined approaches.

Harvard Citation style: Fritzenwanker, M., Imirzalioglu, C., Herold, S., Wagenlehner, F., Zimmer, K. and Chakraborty, T. (2018) Treatment Options for Carbapenem-Resistant Gram-Negative Infections, Deutsches Ärzteblatt International, 115(20-21), pp. 345-34+. https://doi.org/10.3238/arztebl.2018.0345

APA Citation style: Fritzenwanker, M., Imirzalioglu, C., Herold, S., Wagenlehner, F., Zimmer, K., & Chakraborty, T. (2018). Treatment Options for Carbapenem-Resistant Gram-Negative Infections. Deutsches Ärzteblatt International. 115(20-21), 345-34+. https://doi.org/10.3238/arztebl.2018.0345